http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 백희조 ( Hee Jo Baek ) (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
Long-term recombinant interferon-γ treatment in 2 cases of osteopetrosis
김동연,한동균,백희조,정성택,국훈,Kim, Dong-Yun,Han, Dong-Kyun,Baek, Hee-Jo,Jung, Sung-Taek,Kook, Hoon,Hwang, Tai-Ju The Korean Pediatric Society 2007 Clinical and Experimental Pediatrics (CEP) Vol.50 No.11
골화석증은 뼈파괴세포의 기능의 이상과 백혈구의 과산화물 생성 이상을 특징으로 하는 드문 골경화성 질환으로, 유전방법이나 발병나이, 증상, 증상의 정도 등에 따라 몇 가지 아형으로 분류된다. 악성형 골화석증의 궁극적 치료 방법은 조혈모세포이식이지만, 조직형 일치 공여자가 없는 경우나 비교적 양성인 만성형 골화석증에서는 스테로이드나 carcitriol, 인터페론 감마 등의 치료를 시도해 볼 수 있다. 특히 인터페론 감마 치료는 골흡수를 증가시키고, 조혈 기능과 백혈구 기능을 향상시킨다고 보고되고 있다. 본 저자들은 약 6년, 3년 동안 인터페론 감마 치료 후 각각 수혈, 골절과 같은 다른 합병증 없이 조절되고 있는 골화석증 2례에 대해 보고하는 바이다. Osteopetrosis, a rare osteosclerotic bone disease characterized by a defect in osteoclast function and the reduced generation of superoxide by leukocytes, can be classified into several types based on their mode of inheritance, age of onset, severity, and associated clinical symptoms. Stem cell transplantation is the only curative therapy for the infantile malignant type, although alternative treatments, such as corticosteroids, calcitriol, and interferon (IFN)-${\gamma}$ have been attempted in patients with milder clinical types. In addition, IFN-${\gamma}$ therapy has been reported to increase bone resorption and hematopoiesis and to improve leukocyte function. Here, we present the cases of two patients with osteopetrosis who benefited from either 3 or 6 years of INF-${\gamma}$ therapy that resulted in improved blood counts and no further pathological fractures.
-
소아 백혈병 환자의 동종 조혈모세포이식 전처치로서 전신방사선 조사 포함군과 비포함군의 비교
김상정,한동균,백희조,김동연,남택근,황태주,국훈,Kim, Sang-Jeong,Han, Dong-Kyun,Baek, Hee-Jo,Kim, Dong-Yeon,Nam, Taek-Keun,Hwang, Tai-Ju,Kook, Hoon 대한소아청소년과학회 2010 Clinical and Experimental Pediatrics (CEP) Vol.53 No.4
목 적 : 본 연구의 목적은 소아백혈병 환자에서 이식 전처치로서 전신방사선조사(total body irradiation, TBI)군과 비방사선조사(non-TBI)군과의 이식 성적 및 예후를 비교하고자 하였다. 방 법: 1996년 1월에서 2007년 12월까지 전남대학교병원에서 조혈모세포이식을 시행 받은 소아백혈병 환자 77명을 TBI군(n=40)과 non-TBI군(n=37)으로 나누어 각 군 간의 이식 유형, 이식 시 질병상태, 전처치 방법, 이식 세포 수, 생착 속도, 이식편대숙주반응(graft-versus-host disease, GVHD)의 발생빈도, 이식 합병증, 사망원인, 전체생존율(overall survival, OS)과 무사건생존율(event free survival, EFS) 및 후기 합병증을 비교 분석하였다. 결 과 : 급성림프구성백혈병(acute lymphoblastic leukemia, ALL) 환자의 82.4% (28/34)는 TBI를 받았고, 골수계열 백혈병 환자의 72.7% (24/33)는 non-TBI 군이었다. 전체 환자를 대상으로 TBI 여부에 따른 5년 EFS은 두 군간 차이는 없었으나 (62% vs. 63%), ALL 환자에서는 TBI군이 non-TBI군에 비해 통계적으로 유의하게 우수한 5년 EFS을 보였다(65% vs. 17%; $P$=0.005). AML (acute myelogenous leukemia) 환자에서는 non-TBI군이 TBI군보다 더 높은 5년 EFS을 보였으나 통계적인 유의성은 없었다(73% vs. 38 %; $P$=0.089). GVHD 발생률, 생착, 사망원인과 후기 합병증은 두 군간 차이는 없었다. 결 론 : 전처치로서 TBI군과 non-TBI군은 비슷한 결과를 보였으나, ALL환자에서는 TBI군이 non-TBI군에 비하여 유의하게 우수한 5년 EFS을 보였다. 두 군간 후기 합병증의 발생 및 사회경제적 삶의 질을 비교하기 위하여는 많은 환자를 대상으로한 전향적 무작위 연구가 필요하리라 사료된다. Purpose : This study aims to compare the outcome of total body irradiation (TBI)- or non-TBI-containing conditioning regimens for leukemia in children. Methods : We retrospectively evaluated 77 children conditioned with TBI (n=40) or non-TBI (n=37) regimens, transplanted at Chonnam National University Hospital between January 1996 and December 2007. The type of transplantation, disease status at the time of transplant, conditioning regimen, engraftment kinetics, development of graft-versus-host disease (GVHD), complications, cause of deaths, overall survival (OS), and event-free survival (EFS) were compared between the 2 groups. Results : Among 34 patients with acute lymphoblastic leukemia (ALL), 28 (82.4%) were in the TBI group, while 72.7% (24/33) of patients with myeloid leukemia were in the non-TBI group. Although the 5-year EFS of the 2 groups was similar for all patients (62% vs 63%), the TBI group showed a better 5-year EFS than the non-TBI group when only ALL patients were analyzed (65% vs 17%; $P$=0.005). In acute myelogenous leukemia patients, the non-TBI group had better survival tendency (73% vs 38%; $P$=0.089). The incidence of GVHD, engraftment, survival, cause of death, and late complications was not different between the 2 groups. Conclusion : The TBI and non-TBI groups showed comparable results, but the TBI group showed a significantly higher 5-year EFS than the non-TBI group in ALL patients. Further prospective, randomized controlled studies involving larger number of patients are needed to assess the late-onset complications and to compare the socioeconomic quality of life.
-
급성 골수성 백혈병에서 이식 편대 숙주반응 치료 중 발생한 노르웨이 옴
임세웅 ( Se Woong Lim ),윤숙정 ( Sook Jung Yun ),최우연 ( Woo Yeon Choi ),백희조 ( Hee Jo Baek ),국훈 ( Hoon Kook ),이지범 ( Jee Bum Lee ),김성진 ( Seong Jin Kim ),원영호 ( Young Ho Won ),이승철 ( Seung Chul Lee ) 대한피부과학회 2007 대한피부과학회지 Vol.45 No.8
Norwegian scabies is a crusted non-itchy rash caused by massive infestation with the mite Sarcoptes scabiei. It is usually associated with immunosuppression or neurologic impairment, although it has rarely been reported in normal persons. We report a case of Norwegian scabies in 6-year old girl with acute myeloid leukemia associated graft-versus-host disease. The lesion showed pruritic, hyperkeratotic scaly plaques and fissures on the entire body. Application of a mineral oil preparation from hyperkeratotic areas showed numerous scabies mites. Treatment with 10% crotamiton cream for two weeks resulted in marked regression of the skin lesions, but finally she died of sepsis due to deterioration of her systemic conditions. (Korean J Dermatol 2007;45(8):836∼839)
-
면역관용요법을 시행 중인 A형 혈우병 환자에서 에미시주맙의 예방적 사용요법에 대한 체계적 문헌고찰
김아영(Ah-Young Kim),조윤(Yoon Cho),강서윤(Seoyoon Kang),박영실(Young Shil Park),백희조(Hee Jo Baek),이한길(Hankil Lee) 대한약학회 2023 약학회지 Vol.67 No.2
Objective: The use of Emicizumab, a novel agent in hemophilia A, in patients with Hemophilia A undergoing immune tolerance induction (ITI) have been currently evolving in overseas. Here, we aimed to evaluate the real-world use and conceptual study of emicizumab use during ITI in patients with Hemophilia A. Methods: We searched PubMed, Embase, and Cochrane Library databases to perform systematic review according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). Search terms include ‘hemophilia‘, ‘immune tolerance and ‘Emicizumab’. Hemophilia other than hemophilia A, studies with no relevant outcomes, emicizumab use other than during ITI were excluded. Results: Among 419 relevant studies, ten eligible studies were included in this review. Six studies reported real-world prophylactic use of emicizumab during ITI, and total of nineteen subjects, including overlapping patients, were evaluated. Other four studies reported conceptual study design of emicizumab in patients with hemophilia A undergoing ITI. Majority of study set the dose of emicizumab as 1.5mg/kg weekly or 3.0mg/kg bi-weekly after a loading dose of 3.0mg/kg for 4 weeks. In real-world prophylactic use studies, ITI outcome, inhibitor recurrence, antibody titer, adverse events, and FVIII activity were evaluated as outcomes. Conclusion: This study identified the current status of emicizumab use and made evidence for the applicability of emicizumab in patients with hemophilia A undergoing ITI.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
